Quidel (QDEL) has now received Emergency Use Authorization (EUA) from the US FDA for its Sofia 2 SARS Antigen FIA, a rapid point-of-care test for suspected COVID-19 infection.According to the FDA, this is a new category of tests that will now be available for use in the ongoing pandemic. “The antigen diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs” the FDA says.One of the main advantages of an antigen test is the speed of the test, which can provide results in minutes. However, antigen tests …read more
Source:: Yahoo Finance
